Approved Equities, Voluntary Recall, and New Product Launches - Analyst Notes on Baxter, Agilent, InterMune, Intuitive Surgical,

Approved Equities, Voluntary Recall, and New Product Launches - Analyst Notes
        on Baxter, Agilent, InterMune, Intuitive Surgical, and Mindray

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, March 14, 2014

NEW YORK, March 14, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Baxter
International Inc. (NYSE: BAX), Agilent Technologies Inc. (NYSE: A), InterMune
Inc. (NASDAQ: ITMN), Intuitive Surgical, Inc. (NASDAQ: ISRG), and Mindray
Medical International Ltd (NYSE: MR). Private wealth members receive these
notes ahead of publication. To reserve complementary membership, limited
openings are available at: http://www.AnalystsReview.com/register

--

Baxter International Inc. Analyst Notes

On March 5, 2014, Baxter International Inc. (Baxter) initiated a voluntary
recall of a single lot of DIANEAL PD-2 Peritoneal Dialysis Solution with 1.5%
Dextrose 6000mL (Ambu-Flex II) to the hospital/user level in the United
States. According to Baxter, the recall was due to mold caused by a leak in
the container. The Company has sent notifications by recall letter instructing
customers to locate and remove any affected product from their facility. All
patients who received product from the affected lot also were contacted by
recall letter and provided instructions to arrange for product return.
Dialysis centers, facilities, distributors and patients should stop use and
return to place of purchase. According to the Company, the affected lot was
distributed to customers between May 2013 and January 2014. The full analyst
notes on Baxter International Inc. are available to download free of charge
at:

http://www.AnalystsReview.com/03142014/BAX/report.pdf

--

Agilent Technologies Inc. Analyst Notes

On March 11, 2014, Agilent Technologies Inc. (Agilent) introduced the world's
highest-performance oscilloscope - the Infiniium Z-Series oscilloscope. The
Z-Series can be synchronized to simultaneously measure up to 40 channels with
a maximum of 63-GHz real-time oscilloscope bandwidth (on up to 10
oscilloscopes). "The Z-Series further solidifies Agilent's leadership in the
high-end oscilloscope market," said Jay Alexander, Vice President and General
Manager of Agilent's Oscilloscope and Protocol Division. "With its processing
power and new user interface, the new series helps engineers bring products
using emerging technologies to market significantly faster. Several Z-Series
oscilloscopes have already been deployed around the world and are now the
go-to instrument in those laboratories." The Z-Series offers 10 models ranging
from 20-60 GHz, all of which are bandwidth-upgradable to 63 GHz. The full
analyst notes on Agilent Technologies Inc. are available to download free of
charge at:

http://www.AnalystsReview.com/03142014/A/report.pdf

--

InterMune Inc. Analyst Notes

On March 11, 2014, shares of InterMune Inc. (InterMune) slipped 1.37% to end
trading at $33.18. Over the past five-day trading period, InterMune's stock
jumped 4.49%, while the Nasdaq Composite dipped by 1.03% during that same
period. The full analyst notes on InterMune Inc. are available to download
free of charge at:

http://www.AnalystsReview.com/03142014/ITMN/report.pdf

--

Intuitive Surgical, Inc. Analyst Notes

On March 11, 2014, Intuitive Surgical, Inc. (Intuitive Surgical) announced
that the Compensation Committee of its Board of Directors approved equity
awards to 26 new employees. The 26 employees were granted a combination of
Restricted Stock Units (RSUs) and Stock Options to purchase an aggregate of
3,134 shares of the Company's common stock; 2,389 of the shares granted were
Stock Options and 745 of the shares granted were RSUs. Both the RSUs and Stock
Options vest over four years. The Stock Options expire in 10 years assuming
continued employment. No officers received any award under this plan, and the
exercise price for the Stock Options granted was $443.98. The equity awards
were granted under the Company's 2009 Commencement Incentive Plan which was
adopted by the Board for the granting of equity awards to new employees. The
full analyst notes on Intuitive Surgical, Inc. are available to download free
of charge at:

http://www.AnalystsReview.com/03142014/ISRG/report.pdf

--

Mindray Medical International Ltd Analyst Notes

On March 7, 2014, Mindray Medical International Ltd (Mindray) announced that
its ADS' holders of record as of March 14, 2014 are entitled to the recently
declared dividend of $0.50 per ordinary share, payable on or around April 8,
2014. Each Mindray ADS corresponds to one ordinary share. The record date for
Mindray's ordinary shares (previously announced as March 8, 2014) will also be
March 14, 2014. The Company also announced that dividends paid to its ADS
holders via the depositary bank will be subject to the terms of the deposit
agreement, including the fees and expenses payable thereunder. The full
analyst notes on Mindray Medical International Ltd are available to download
free of charge at:

http://www.AnalystsReview.com/03142014/MR/report.pdf

--

About Analysts Review
We provide our members with a simple and reliable way to leverage our economy
of scale. Most investors do not have time to track all publicly traded
companies, much less perform an in-depth review and analysis of the
complexities contained in each situation. That's where Analysts Review comes
in. We provide a single unified platform for investors' to hear about what
matters. Situation alerts, moving events, and upcoming opportunities.

--

=============

EDITOR NOTES:

  oThis is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
  oInformation in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
  oThis information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
  oIf you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at pubco [at]
    AnalystsReview.com.
  oFor any urgent concerns or inquiries, please contact us at compliance [at]
    AnalystsReview.com.
  oAre you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to research [at]
    AnalystsReview.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Analysts Review. An
outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Analysts Review in this article or
report according to the Procedures outlined by Analysts Review. Analysts
Review is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Analysts Review makes no warranty, expressed or implied, as to the accuracy or
completeness or fitness for a purpose (investment or otherwise), of the
information provided in this document. This information is not to be construed
as personal financial advice. Readers are encouraged to consult their personal
financial advisor before making any decisions to buy, sell or hold any
securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Analysts Review is not responsible for any error which may be occasioned at
the time of printing of this document or any error, mistake or shortcoming. No
liability is accepted by Analysts Review whatsoever for any direct, indirect
or consequential loss arising from the use of this document. Analysts Review
expressly disclaims any fiduciary responsibility or liability for any
consequences, financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1) guarantee the
accuracy, timeliness, completeness or correct sequencing of the information,
or (2) warrant any results from use of the information. The included
information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsReview.com

SOURCE Analysts Review

Contact: Adam Redford, +852-8191-3972
 
Press spacebar to pause and continue. Press esc to stop.